COVID-19 vaccines have been essential in bringing the pandemic under control. They have shown to be highly efficacious against severe diseases
ReadThe SARS-CoV-2 Omicron recombinant XBB subvariant was first detected in September 2022, and rapidly spread across South-East Asia, notably overtaking BA.5 to become the dominant variant in Singapore.
ReadPositive-strand RNA viruses have been the cause of several recent outbreaks and epidemics, including the Zika virus epidemic in 2015, the SARS outbreak in 2003, and the ongoing SARS-CoV-2 pandemic.
ReadSARS-CoV-2 was first detected in late December 2019, however, in the few months that followed, the resultant COVID-19 disease has developed into a devastating pandemic around the world [[1]]. This has led to a race to produce a safe and efficacious vaccine in record time.
ReadMore than one-third of the world’s population is exposed to Plasmodium vivax malaria, mainly in Asia1. P. vivax preferentially invades reticulocytes (immature red blood cells)2,3,4. Previous work has identified 11 parasite proteins involved in reticulocyte invasion, including erythrocyte binding protein 2 (ref. 5) and the reticulocyte-binding proteins (PvRBPs)6,7,8,9,10.
ReadSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants with a 382-nucleotide deletion (∆382) in the open reading frame 8 (ORF8) region of the genome have been detected in Singapore and other countries. We investigated the effect of this deletion on the clinical features of infection.
Read